Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture for manufacturing, CoSara Diagnostics Pvt Ltd, has obtained regulatory clearance for five tests to be manufa...

New York City, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) , a biotech company with a patented platform for the development of molecular diagnostic tests, released what could arguably be the most significant news in its history earlier today with the announcement ...

CoSara Saragene™ tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus now available for sale and distribution as in vitro diagnostics Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a uniq...